NATICK, MA--(Marketwired - Feb 13, 2014) - Dr. Colin White, newly-appointed chief scientific officer at Parcell Laboratories, will speak on the scientific foundation for the company's patented ELA® cell platform technology and on the benefits it offers to allogeneic cell-based therapies at two conferences next week. He will share his thoughts on the first-mover advantages surrounding allograft cell-based products at the New York Stem Cell Summit '14 on February 18. At the Global Technology Community's Cell & Gene Therapy Conference in San Diego on February 20, Dr. White will lecture on the discovery, isolation and characterization of the ELA cell, describing how ELA cells represent a novel source of stem cells for the potential treatment of numerous diseases.
"Parcell Labs will be unveiling its platform technology, backed by clinical data that supports our work, to the world's scientific community at the Global Technology Community's Cell & Gene Therapy Conference," said Dr. White. "It will be the first opportunity we've had to share our research and development efforts with the world. At the New York Stem Cell Summit, we will showcase our first-mover perspective on the regulatory pathway of cell-based therapies, the necessities of and hard work behind delivering a robust quality system, and our clinical data to date."
At the New York Stem Cell Summit, Dr. White will join a panel of industry professionals to discuss the first-mover advantage of allograft cell-based products, which have already generated more than $200 million in hospital purchases in 2013. As first-movers, Dr. White and the other panelists will discuss the manufacturing processes and regulatory pathways for cell-based products, as well as their safety, efficacy and the physician response.
Dr. White's presentation at the Global Technology Community's Cell & Gene Therapy Conference will include a detailed report on the discovery, isolation and characterization of a novel population of synovial fluid-derived adult stem cells, which Parcell Labs has termed Early Lineage Adult (ELA) stem cells. In vitro studies reveal that ELA cells differentiate into tissues of ectodermal, mesodermal, and endodermal origins, and in vivo studies demonstrate that ELA cells harbor a significant osteogenic differentiation capacity. Clinically, an ELA cell-based therapy has been developed and used commercially in approximately 3,500 surgical procedures for spinal fusion, and a retrospective chart review of treated patients revealed promising results, with detectable fusion as early as six months post-surgery and no attributable adverse events. Parcell Labs' data indicate that ELA cells likely represent a novel source of stem cells for the potential treatment of numerous diseases.
About Parcell Laboratories
Parcell Laboratories, Inc., founded in 2008, develops novel therapeutics based on its patented adult stem cell platform technology, the ELA® cell. The ELA cell was discovered by scientists affiliated with the Brigham and Women's Hospital and Harvard Medical School, who demonstrated the vast potential of the technology in regenerative medicine. ELA cells are found in various tissues throughout the body and are characterized by a specific surface marker profile that set them apart from other adult stem cells. Based in Natick, Mass., the company's state-of-the-art research, processing, storage and fulfillment facilities set the stage for the future of adult stem cells and regenerative medicine. For more information, visit www.parcelllabs.com. Parcell Laboratories is a member of the Parcell Group of companies, which also includes CellCure Trust, LLC and Cellogx, LLC.